These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27814715)

  • 1. Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer.
    Amin S; Bathe OF
    BMC Cancer; 2016 Nov; 16(1):850. PubMed ID: 27814715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of individual response to anticancer therapy: historical and future perspectives.
    Unger FT; Witte I; David KA
    Cell Mol Life Sci; 2015 Feb; 72(4):729-57. PubMed ID: 25387856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The arrival of predictive biomarkers for monitoring therapy response to natural compounds in cancer drug discovery.
    El Bairi K; Atanasov AG; Amrani M; Afqir S
    Biomed Pharmacother; 2019 Jan; 109():2492-2498. PubMed ID: 30551510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics and pharmacogenomics as tools in cancer therapy.
    Rodríguez-Vicente AE; Lumbreras E; Hernández JM; Martín M; Calles A; Otín CL; Algarra SM; Páez D; Taron M
    Drug Metab Pers Ther; 2016 Mar; 31(1):25-34. PubMed ID: 26863347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring for Response to Antineoplastic Drugs: The Potential of a Metabolomic Approach.
    Rattner J; Bathe OF
    Metabolites; 2017 Nov; 7(4):. PubMed ID: 29144383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances.
    Lech G; Słotwiński R; Słodkowski M; Krasnodębski IW
    World J Gastroenterol; 2016 Feb; 22(5):1745-55. PubMed ID: 26855534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Precision medicine from experimental to clinical applications in oncology].
    Normanno N
    Recenti Prog Med; 2015 Dec; 106(12):597-600. PubMed ID: 26780068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A New Look at Toxicity in the Era of Precision Oncology: Imaging Findings, Their Relationship With Tumor Response, and Effect on Metastasectomy.
    Howard SA; Krajewski KM; Jagannathan JP; Braschi-Amirfarzan M; Tirumani SH; Shinagare AB; Ramaiya NH
    AJR Am J Roentgenol; 2016 Jul; 207(1):4-14. PubMed ID: 27065346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on Biomarkers in Development of Anti-angiogenic Drugs in Gastric Cancer.
    Jia S; Cai J
    Anticancer Res; 2016 Mar; 36(3):1111-8. PubMed ID: 26977006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation.
    Alymani NA; Smith MD; Williams DJ; Petty RD
    Eur J Cancer; 2010 Mar; 46(5):869-79. PubMed ID: 20138504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation.
    Carpinetti P; Donnard E; Bettoni F; Asprino P; Koyama F; Rozanski A; Sabbaga J; Habr-Gama A; Parmigiani RB; Galante PA; Perez RO; Camargo AA
    Oncotarget; 2015 Nov; 6(35):38360-71. PubMed ID: 26451609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
    Tan DS; Thomas GV; Garrett MD; Banerji U; de Bono JS; Kaye SB; Workman P
    Cancer J; 2009; 15(5):406-20. PubMed ID: 19826361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What have we learned from exceptional tumour responses?: Review and perspectives.
    Mehra N; Lorente D; de Bono JS
    Curr Opin Oncol; 2015 May; 27(3):267-75. PubMed ID: 25811347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A decision support framework for genomically informed investigational cancer therapy.
    Meric-Bernstam F; Johnson A; Holla V; Bailey AM; Brusco L; Chen K; Routbort M; Patel KP; Zeng J; Kopetz S; Davies MA; Piha-Paul SA; Hong DS; Eterovic AK; Tsimberidou AM; Broaddus R; Bernstam EV; Shaw KR; Mendelsohn J; Mills GB
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient, Adaptive Clinical Validation of Predictive Biomarkers in Cancer Therapeutic Development.
    Beckman RA; Chen C
    Adv Exp Med Biol; 2015; 867():81-90. PubMed ID: 26530361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The identification of clinically relevant markers and therapeutic targets.
    Nicolette CA; Miller GA
    Drug Discov Today; 2003 Jan; 8(1):31-8. PubMed ID: 12546989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validated biomarkers: The key to precision treatment in patients with breast cancer.
    Duffy MJ; O'Donovan N; McDermott E; Crown J
    Breast; 2016 Oct; 29():192-201. PubMed ID: 27521224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Biomarkers in solid tumors].
    Nagy Z
    Magy Onkol; 2013 Mar; 57(1):56-62. PubMed ID: 23573523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QA procedures for multimodality preclinical tumor drug response testing.
    Lee YC; Goins BA; Fullerton GD
    Med Phys; 2010 Sep; 37(9):4806-16. PubMed ID: 20964200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.